<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Ter Intensiva</journal-id><journal-id journal-id-type="iso-abbrev">Rev Bras Ter Intensiva</journal-id><journal-title-group><journal-title>Revista Brasileira de Terapia Intensiva</journal-title></journal-title-group><issn pub-type="ppub">0103-507X</issn><issn pub-type="epub">1982-4335</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o Brasileira de Medicina
intensiva</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25909311</article-id><article-id pub-id-type="pmc">4396895</article-id><article-id pub-id-type="doi">10.5935/0103-507X.20150007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Blood transfusions in septic shock: is 7.0g/dL really the appropriate
threshold?</article-title><trans-title-group xml:lang="pt"><trans-title>Transfus&#x000f5;es de sangue no choque s&#x000e9;ptico: 7,0g/dL &#x000e9;
mesmo o limite adequado?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mazza</surname><given-names>Bruno Franco</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Freitas</surname><given-names>Flavio Geraldo Rezende</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Barros</surname><given-names>Melca Maria Oliveira</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Azevedo</surname><given-names>Luciano Cesar Pontes</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Machado</surname><given-names>Flavia Ribeiro</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib></contrib-group><aff id="aff01"><label>1</label>Department of Anesthesiology, Pain and Intensive Care, Universidade
Federal de S&#x000e3;o Paulo - S&#x000e3;o Paulo (SP), Brazil.</aff><aff id="aff02"><label>2</label>Department of Hematology, Universidade Federal de S&#x000e3;o Paulo -
S&#x000e3;o Paulo (SP), Brazil.</aff><author-notes><corresp id="c01"><bold>Corresponding author:</bold> Bruno Franco Mazza, Departamento de
Anestesiologia, Dor e Terapia Intensiva da Universidade Federal de S&#x000e3;o Paulo,
Rua Napole&#x000e3;o de Barros 715 - 5&#x000ba; floor, Zip code: 04024-900 - S&#x000e3;o
Paulo (SP), Brazil. E-mail: <email>bruno.mazza@live.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Mar</season><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2015</year></pub-date><volume>27</volume><issue>1</issue><fpage>36</fpage><lpage>43</lpage><history><date date-type="received"><day>11</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>02</day><month>2</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To evaluate the immediate effects of red blood cell transfusion on central venous
oxygen saturation and lactate levels in septic shock patients with different
transfusion triggers.</p></sec><sec><title>Methods</title><p>We included patients with a diagnosis of septic shock within the last 48 hours and
hemoglobin levels below 9.0g/dL Patients were randomized for immediate transfusion
with hemoglobin concentrations maintained above 9.0g/dL (Group Hb9) or to withhold
transfusion unless hemoglobin felt bellow 7.0g/dL (Group Hb7). Hemoglobin,
lactate, central venous oxygen saturation levels were determined before and one
hour after each transfusion.</p></sec><sec><title>Results</title><p>We included 46 patients and 74 transfusions. Patients in Group Hb7 had a
significant reduction in median lactate from 2.44 (2.00 - 3.22) mMol/L to 2.21
(1.80 - 2.79) mMol/L, p = 0.005, which was not observed in Group Hb9 [1.90
(1.80 - 2.65) mMol/L to 2.00 (1.70 - 2.41) mMol/L, p = 0.23]. Central
venous oxygen saturation levels increased in Group Hb7 [68.0 (64.0 - 72.0)%
to 72.0 (69.0 - 75.0)%, p &#x0003c; 0.0001] but not in Group Hb9 [72.0
(69.0 - 74.0)% to 72.0 (71.0 - 73.0)%, p = 0.98]. Patients with elevated
lactate or central venous oxygen saturation &#x0003c; 70% at baseline had a significant
increase in these variables, regardless of baseline hemoglobin levels. Patients
with normal values did not show a decrease in either group.</p></sec><sec><title>Conclusion</title><p>Red blood cell transfusion increased central venous oxygen saturation and
decreased lactate levels in patients with hypoperfusion regardless of their
baseline hemoglobin levels. Transfusion did not appear to impair these variables
in patients without hypoperfusion.</p><p><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> NCT01611753</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>Objetivo</title><p>Avaliar os efeitos imediatos da transfus&#x000e3;o de hem&#x000e1;cias nos
n&#x000ed;veis de satura&#x000e7;&#x000e3;o venosa central de oxig&#x000ea;nio e de
lactato em pacientes com choque s&#x000e9;ptico usando diferentes n&#x000ed;veis
gatilho de hemoglobina para indicar transfus&#x000e3;o.</p></sec><sec><title>M&#x000e9;todos</title><p>Inclu&#x000ed;mos pacientes com diagn&#x000f3;stico de choque s&#x000e9;ptico nas
&#x000fa;ltimas 48 horas e n&#x000ed;veis de hemoglobina abaixo de 9,0g/dL. Os
pacientes foram randomizados para receber imediatamente transfus&#x000e3;o se as
concentra&#x000e7;&#x000f5;es se mantivessem acima de 9,0g/dL (Grupo Hb9) ou adiar a
transfus&#x000e3;o at&#x000e9; que a hemoglobina ca&#x000ed;sse abaixo de 7,0g/dL
(Grupo Hb7). Os n&#x000ed;veis de hemoglobina, lactato e satura&#x000e7;&#x000e3;o
venosa central de oxig&#x000ea;nio foram determinados antes e 1 hora ap&#x000f3;s
cada transfus&#x000e3;o.</p></sec><sec><title>Resultados</title><p>Inclu&#x000ed;mos 46 pacientes, totalizando 74 transfus&#x000f5;es. Os pacientes do
Grupo Hb7 tiveram uma redu&#x000e7;&#x000e3;o significante nos n&#x000ed;veis
medianos de lactato de 2,44 (2,00 - 3,22) mMol/L para 2,21 (1,80 - 2,79) mMol/L; p
= 0,005. Isto n&#x000e3;o foi observado no Grupo Hb9 [1,90 (1,80 - 2,65)
mMol/L para 2,00 (1,70 - 2,41) mMol/L; p = 0,23]. A satura&#x000e7;&#x000e3;o
venosa central de oxig&#x000ea;nio aumentou no Grupo Hb7 [68,0 (64,0 -
72,0)% para 72,0 (69,0 - 75,0)%; p &#x0003c; 0,0001], mas n&#x000e3;o no Grupo
Hb9 [72,0 (69,0 - 74,0)% para 72,0 (71,0 - 73,0)%; p = 0,98].
Pacientes com elevados n&#x000ed;veis de lactato ou satura&#x000e7;&#x000e3;o venosa
central de oxig&#x000ea;nio menor que 70% na avalia&#x000e7;&#x000e3;o basal tiveram
um aumento significante nessas vari&#x000e1;veis, independentemente dos
n&#x000ed;veis basais de hemoglobina. Pacientes com valores normais n&#x000e3;o
demonstraram diminui&#x000e7;&#x000e3;o em quaisquer dos grupos.</p></sec><sec><title>Conclus&#x000e3;o</title><p>A transfus&#x000e3;o de hem&#x000e1;cias aumentou a satura&#x000e7;&#x000e3;o venosa
central de oxig&#x000ea;nio e diminuiu os n&#x000ed;veis de lactato em pacientes com
hipoperfus&#x000e3;o, independentemente de seus n&#x000ed;veis basais de
hemoglobina. A transfus&#x000e3;o n&#x000e3;o pareceu influenciar essas
vari&#x000e1;veis em pacientes sem hipoperfus&#x000e3;o.</p><p><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> NCT01611753</p></sec></trans-abstract><kwd-group><kwd>Erythrocyte transfusion</kwd><kwd>Ischemia</kwd><kwd>Shock, septic</kwd><kwd>Sepsis</kwd><kwd>Oxygenation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Sepsis is a common condition associated with both high costs and mortality and is
usually related to multiple organ dysfunction.<sup>(<xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r08" ref-type="bibr">8</xref>)</sup> One of the primary
mechanisms for organ dysfunction is inadequate cellular metabolism due to alterations in
oxygen supply and consumption.<sup>(<xref rid="r09" ref-type="bibr">9</xref>)</sup>
Adequate hemoglobin (Hb) levels could theoretically increase arterial oxygen content and
thus improve tissue oxygen delivery.<sup>(<xref rid="r10" ref-type="bibr">10</xref>)</sup> However, there are no conclusive data regarding the optimal level
of Hb in septic shock patients.<sup>(<xref rid="r11" ref-type="bibr">11</xref>)</sup></p><p>Although it is not clear that alterations in the central venous oxygen saturation
(ScvO<sub>2</sub>) and lactate levels actually represent improvements in the oxygen
delivery/oxygen consumption ratio these alterations may be a better indication for
transfusion than the absolute Hb value. Studies on the effects of transfusion on oxygen
transport variables have yielded conflicting results, with some trials showing an
increase in oxygen delivery/oxygen consumption ratio while others show no
increase.<sup>(<xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r17" ref-type="bibr">17</xref>)</sup> Some authors have recently suggested that these
variables could help to identify surgical patients who would benefit from
transfusion.<sup>(<xref rid="r18" ref-type="bibr">18</xref>)</sup> Others have
shown that muscle tissue oxygenation, oxygen consumption and microvascular reactivity as
assessed by near-infrared spectroscopy improve after transfusion only in patients with
alterations in these variables at baseline.<sup>(<xref rid="r19" ref-type="bibr">19</xref>)</sup></p><p>Rivers et al. demonstrated a significant reduction in hospital mortality rates among
patients who were randomized to undergo early goal-directed therapy that included red
blood cell (RBC) transfusion.<sup>(<xref rid="r20" ref-type="bibr">20</xref>)</sup>
However, a clear relationship between blood transfusion and improved outcomes could not
be demonstrated with this type of study. Recently, Holst et al. randomized 998 septic
shock patients to a restrictive or liberal transfusion strategy;<sup>(<xref rid="r21" ref-type="bibr">21</xref>)</sup> they could not find any difference
between those patients assigned to be transfused only if Hb levels were below 7.0 and
those with Hb 9.0g/dL as a trigger. However, those patients were transfused throughout
their intensive care unit (ICU) stay, regardless of their tissue oxygenation variables,
which reduces the relevance of the study&#x02019;s findings. The primary controversy concerns
the potential benefits of transfusion in patients with signs of hypoperfusion and Hb
levels over 7.0g/dL.</p><p>Therefore, we designed a physiological study to determine the effects of RBC transfusion
on ScvO<sub>2</sub> and lactate levels in septic shock patients who were randomized into
two groups with different Hb levels. Although increased Hb levels will hypothetically
increase oxygen content and oxygen delivery on a mathematical basis, we hypothesized
that this would increase SvcO<sub>2</sub> only if Hb levels were below 7.0g/dL. It is
possible that with higher Hb levels, this contribution differs from lower levels, which
supports a restrictive approach to transfusion. The goal of this study was to test this
hypothesis in random populations of patients in whom transfusion was indicated as Hb
fell below 9.0g/dL and in those for whom transfusion was withheld until Hb fell below
7.0g/dL.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients</title><p>This multi-center, prospective, randomized study was conducted in three Brazilian
general ICU with a total of 55 beds. Patients who were admitted to one of the
participant ICUs with a diagnosis of septic shock<sup>(<xref rid="r22" ref-type="bibr">22</xref>)</sup> between March 1<sup>st</sup> and August
31<sup>st</sup> 2008 were included on a non-consecutive basis if they fulfilled
the following inclusion criteria: age over 18 years old, a shock diagnosis that was
made less than 48 hours prior to participation in the study, Hb levels less than
9.0g/dL and a central venous catheter in the superior vena cava. The exclusion
criteria were as follows: pregnancy, known coronary disease, active bleeding and
previous participation in the study. The Ethical Committee of the coordinating center
approved the study under number 1,177/04, and the trial was registered at
ClinicalTrials.gov (NCT01611753). All patients or their legal representatives signed
informed consents.</p></sec><sec><title>Red blood cell transfusion characteristics</title><p>Packed RBCs were obtained from the blood bank at each participating site. None of the
RBC units transfused in this study was leukoreduced. Storage solution (citrate
phosphate dextrose adenine - CPDA-1) was routinely added to the RBCs before storage.
The storage period can be extended up to 35 days, and there is no blood bank policy
for preferentially transfusing fresh RBCs in ICU patients.</p></sec><sec><title>Study protocol</title><p>We registered only transfusions received while the patients were in shock using
vasopressors. We randomized all patients into two groups: patients in Group 1
received transfusions immediately so that their Hb levels were maintained above
9.0g/dL; in Group 2, transfusion was withheld until the patients&#x02019; Hb levels fell
below 7.0g/dL. We used sealed envelopes with blocks of 10 in each of the
participating hospitals for randomization. For practical reasons, the attending
physicians and protocol staff were not blinded to the group assignments. Demographic
data and the Acute Physiology And Chronic Health Evaluation II (APACHE II)<sup>(<xref rid="r23" ref-type="bibr">23</xref>)</sup> and Sequential Organ Failure
Assessment (SOFA)<sup>(<xref rid="r24" ref-type="bibr">24</xref>)</sup> severity
scores were determined on the day of inclusion.</p><p>Each time a patient received a transfusion, we collected a set of laboratory tests,
including Hb levels, ScvO<sub>2</sub> and lactate at two time points, once
immediately before transfusion and once one hour after the end of transfusion.
Laboratory tests were collected through a central venous access after discarding 5mL
of blood. The correct position of the central venous catheter was assessed using
chest radiography. Blood gas data and lactate levels were both measured using a
microtechnique in a blood gas analyzer (ABL 700 Radiometer, Copenhagen, Denmark). Hb
levels were measured by spectrophotometry (Cell-din<sup>&#x000ae;</sup>
3700/Abbott<sup>&#x000ae;</sup>, Illinois, USA).</p><p>Immediately prior to each transfusion, we verified that patients had an adequate
volemic state, which was defined by a central venous pressure (CVP) above 12mmHg and
the decision of the assistant physician that patients did not require another fluid
challenge. If the CVP was less than this value, patients received lactated Ringer&#x02019;s
solution or normal saline. Vasopressors were used to maintain the mean arterial
pressure above 70mmHg. Only if clinically required, ventilator parameters,
vasopressors or dobutamine infusion could be adjusted during the study period. In
such a case, the specific transfusion would not be considered in the final
analysis.</p><p>We assessed Hb levels daily to evaluate the need for transfusion, and as soon as the
results became available, patients received an RBC transfusion if required. For each
transfusion, only one unit of RBC was transfused. Every transfusion during the study
period was registered. We followed the patients until death or the resolution of
shock, which was defined as the withdrawal of vasopressors for at least 24 hours.
Thereafter, any transfusion was conducted at the discretion of the attending
physician.</p></sec><sec><title>Statistical analysis</title><p>The primary endpoint of the study was the effect of transfusion on lactate and
ScvO<sub>2</sub>. The pre-specified subgroups were those patients with signs of
hypoperfusion detected using lactate levels at least 1.5 times the normal values and
those with ScvO<sub>2</sub> below 70%. In addition, we also analyzed patients without
signs of hypoperfusion based on normal lactate and ScvO<sub>2</sub> levels.</p><p>The sample size was calculated assuming that ScvO<sub>2</sub> would increase in 80%
of transfusions for patients in Group Hb7, in whom transfusion was withheld until Hb
fell below 7.0g/dL compared to only 45% of those in the group transfused to maintain
Hb above 9.0g/dL with an alpha error of 0.05 and a power of 80%. Improvement was
defined as an increase of 5% over the pre-transfusion ScvO<sub>2</sub>.<sup>(<xref rid="r18" ref-type="bibr">18</xref>)</sup> According to our calculations, 28
transfusions would be necessary in each group; however, to correct for the potential
non-parametric distribution of the primary variables, the number was adjusted to 35
transfusions in each group.</p><p>Categorical variables were compared using the Pearson chi-squared test corrected by
the Mantel-Haenszel method. The distribution of continuous variables was assessed
using the Shapiro-Wilk test, and the homogeneity of variance was assessed using the
Bartlett test. Normally distributed variables with homogeneous variance were
expressed as the mean &#x000b1; standard deviation, and non-parametric variables were
expressed as the median (interquartile 25% - interquartile 75%). Between groups,
<italic>Student&#x02019;s t</italic>-test and the Mann-Whitney test were used. For
comparison within each group, the Wilcoxon paired test was used because Hb, lactate
and ScvO<sub>2</sub> were not normally distributed. We also performed a receiver
operating characteristic (ROC) curve analysis to assess the accuracy of
pre-transfusion Hb levels, pre-transfusion lactate and pre-transfusion
ScvO<sub>2</sub> in predicting patients whose ScvO<sub>2</sub> would increase more
than 5% with transfusion. We did not consider patients with levels above 75% in this
analysis, as the physiological interpretation of this situation is controversial.</p><p>In all tests, the results were considered significant if the p value was less than
0.05. Statistical analyses were conducted using Statistical Package for Social
Science (SPSS) 17.0 and GraphPad Prism 5.0.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Sixty-three patients were included in this study. Overall, there were 74 RBC
transfusions with 39 in Group Hb9 and 35 in Group Hb7 (<xref ref-type="fig" rid="f01">Figure 1</xref>); 19 patients received more than one transfusion. There were no
significant differences between groups regarding demographic variables, severity scores
(<xref ref-type="table" rid="t01">Table 1</xref>) or hemodynamic characteristics
immediately before transfusion (<xref ref-type="table" rid="t02">Table 2</xref>). There
were no changes in respiratory parameters or vasoactive drug infusions, and no patient
received additional fluids during the transfusion period.</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study flowchart.</p><p>Hb - hemoglobin.</p></caption><graphic xlink:href="rbti-27-01-0036-g01"/></fig><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1"><bold>Variable</bold></th><th align="center" rowspan="1" colspan="1"><bold>Global</bold></th><th align="center" rowspan="1" colspan="1"><bold>Liberal</bold></th><th align="center" rowspan="1" colspan="1"><bold>Restrictive</bold></th><th rowspan="2" align="center" colspan="1"><bold>p value</bold></th></tr><tr><th align="center" rowspan="1" colspan="1"><bold>N = 46</bold></th><th align="center" rowspan="1" colspan="1"><bold>N = 24</bold></th><th align="center" rowspan="1" colspan="1"><bold>N = 22</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male gender</td><td align="center" rowspan="1" colspan="1">25 (54.3)</td><td align="center" rowspan="1" colspan="1">14 (58.3)</td><td align="center" rowspan="1" colspan="1">11 (50.0)</td><td align="center" rowspan="1" colspan="1">0.76</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">57.5 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">57.4 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">57.6 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">0.95</td></tr><tr><td rowspan="1" colspan="1">Comorbidities</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Arterial hypertension</td><td align="center" rowspan="1" colspan="1">24 (52.2)</td><td align="center" rowspan="1" colspan="1">12 (50.0)</td><td align="center" rowspan="1" colspan="1">12 (54.5)</td><td align="center" rowspan="1" colspan="1">0.77</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Coronary artery disease</td><td align="center" rowspan="1" colspan="1">17 (37.0)</td><td align="center" rowspan="1" colspan="1">10 (41.7)</td><td align="center" rowspan="1" colspan="1">7 (31.8)</td><td align="center" rowspan="1" colspan="1">0.55</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Congestive heart failure</td><td align="center" rowspan="1" colspan="1">14 (30.4)</td><td align="center" rowspan="1" colspan="1">5 (20.8)</td><td align="center" rowspan="1" colspan="1">9 (40.9)</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Diabetes</td><td align="center" rowspan="1" colspan="1">15 (32.6)</td><td align="center" rowspan="1" colspan="1">9 (37.5)</td><td align="center" rowspan="1" colspan="1">6 (27.3)</td><td align="center" rowspan="1" colspan="1">0.53</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Chronic renal disease</td><td align="center" rowspan="1" colspan="1">22 (47.8)</td><td align="center" rowspan="1" colspan="1">13 (54.2)</td><td align="center" rowspan="1" colspan="1">9 (40.9)</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Chronic pulmonary disease</td><td align="center" rowspan="1" colspan="1">15 (32.6)</td><td align="center" rowspan="1" colspan="1">8 (33.3)</td><td align="center" rowspan="1" colspan="1">7 (31.8)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Chronic hepatic disease</td><td align="center" rowspan="1" colspan="1">8 (17.4)</td><td align="center" rowspan="1" colspan="1">4 (16.7)</td><td align="center" rowspan="1" colspan="1">4 (18.2)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Immunosuppression</td><td align="center" rowspan="1" colspan="1">5 (10.9)</td><td align="center" rowspan="1" colspan="1">2 (8.3)</td><td align="center" rowspan="1" colspan="1">3 (13.6)</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Neoplasm</td><td align="center" rowspan="1" colspan="1">10 (21.7)</td><td align="center" rowspan="1" colspan="1">6 (25.0)</td><td align="center" rowspan="1" colspan="1">4 (18.2)</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Cerebral vascular disease</td><td align="center" rowspan="1" colspan="1">6 (13.0)</td><td align="center" rowspan="1" colspan="1">2 (8.3)</td><td align="center" rowspan="1" colspan="1">4 (18.2)</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td rowspan="1" colspan="1">Source of infection</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Urinary</td><td align="center" rowspan="1" colspan="1">17 (37.0)</td><td align="center" rowspan="1" colspan="1">9 (37.5)</td><td align="center" rowspan="1" colspan="1">8 (36.4)</td><td align="center" rowspan="1" colspan="1">0.80</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Pulmonary</td><td align="center" rowspan="1" colspan="1">16 (34.8)</td><td align="center" rowspan="1" colspan="1">7 (29.2)</td><td align="center" rowspan="1" colspan="1">9 (40.9)</td><td align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Abdominal</td><td align="center" rowspan="1" colspan="1">9 (19.6)</td><td align="center" rowspan="1" colspan="1">5 (20.8)</td><td align="center" rowspan="1" colspan="1">4 (18.2)</td><td align="center" rowspan="1" colspan="1">0.73</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Other</td><td align="center" rowspan="1" colspan="1">4 (8.7)</td><td align="center" rowspan="1" colspan="1">3 (12.5)</td><td align="center" rowspan="1" colspan="1">1 (4.5)</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td rowspan="1" colspan="1">APACHE II</td><td align="center" rowspan="1" colspan="1">14.0 &#x000b1; 3.6</td><td align="center" rowspan="1" colspan="1">13.9 &#x000b1; 3.7</td><td align="center" rowspan="1" colspan="1">14.2 &#x000b1; 3.6</td><td align="center" rowspan="1" colspan="1">0.77</td></tr><tr><td rowspan="1" colspan="1">SOFA</td><td align="center" rowspan="1" colspan="1">6.8 &#x000b1; 0.9</td><td align="center" rowspan="1" colspan="1">6.7 &#x000b1; 0.7</td><td align="center" rowspan="1" colspan="1">6.9 &#x000b1; 1.1</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td rowspan="1" colspan="1">Admission Hb (g/dL)</td><td align="center" rowspan="1" colspan="1">10 (9.1 - 11.0)</td><td align="center" rowspan="1" colspan="1">10 (9.5 - 12.0)</td><td align="center" rowspan="1" colspan="1">9.8 (8.8 - 9.8)</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">Mortality</td><td align="center" rowspan="1" colspan="1">24 (52.1)</td><td align="center" rowspan="1" colspan="1">13 (54)</td><td align="center" rowspan="1" colspan="1">11 (50)</td><td align="center" rowspan="1" colspan="1">0.87</td></tr></tbody></table><table-wrap-foot><fn><p>APACHE - Acute Physiologic and Chronic Health Evaluation; SOFA - Sequential
Organ Failure Assessment; Hb - hemoglobin. The results are expressed as numbers
(%), mean &#x000b1; standard deviation or median (25 - 75%). Chi-square,
<italic>t-student</italic> or Mann-Whitney test used as appropriate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Hemodynamic profile immediately prior to transfusion</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1"><bold>Variable</bold></th><th align="center" rowspan="1" colspan="1"><bold>Global</bold></th><th align="center" rowspan="1" colspan="1"><bold>Liberal</bold></th><th align="center" rowspan="1" colspan="1"><bold>Restrictive</bold></th><th rowspan="2" align="center" colspan="1"><bold>p</bold>
<bold>value</bold></th></tr><tr><th align="center" rowspan="1" colspan="1"><bold>N = 74</bold></th><th align="center" rowspan="1" colspan="1"><bold>N = 39</bold></th><th align="center" rowspan="1" colspan="1"><bold>N = 35</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CVP (cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">17.4 &#x000b1; 2.6</td><td align="center" rowspan="1" colspan="1">17.0 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">17.9 &#x000b1; 2.9</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">Dobutamine use</td><td align="center" rowspan="1" colspan="1">55 (74.3)</td><td align="center" rowspan="1" colspan="1">29 (52.7)</td><td align="center" rowspan="1" colspan="1">26 (47.3)</td><td align="center" rowspan="1" colspan="1">1.00</td></tr><tr><td rowspan="1" colspan="1">Dobutamine dose (&#x003bc;g/kg/min)</td><td align="center" rowspan="1" colspan="1">5.6 &#x000b1; 2.1</td><td align="center" rowspan="1" colspan="1">5.1 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">5.8 &#x000b1; 2.0</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td rowspan="1" colspan="1">Norepinephrine dose (&#x003bc;g/kg/min)</td><td align="center" rowspan="1" colspan="1">0.3 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.3 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.3 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.98</td></tr></tbody></table><table-wrap-foot><fn><p>CVP - central venous pressure. The results are expressed as numbers (%) or mean
&#x000b1; standard deviation. Chi square test, <italic>t-student</italic> or
Mann-Whitney test.</p></fn></table-wrap-foot></table-wrap><p>Transfusion increased global Hb levels (p &#x0003c; 0.0001) and, as expected, the
pre-transfusion Hb levels were higher in the Group Hb9) (p &#x0003c; 0.0001, <xref ref-type="table" rid="t03">Table 3</xref>), and pre-transfusion lactate levels were
higher in Group Hb7. A significant reduction in lactate levels after transfusion could
be found only in Group Hb7 (Group Hb9: p = 0.23, Group Hb7: p = 0.005). Additionally, as
expected, ScvO<sub>2</sub> was significantly lower at baseline in Group Hb7, and an
increase could be detected only in this group (Group Hb9: p = 0.96 and Group Hb7: p &#x0003c;
0.0001). The ROC curves showed that pre-transfusion ScvO<sub>2</sub> levels were better
than the pre-transfusion Hb or lactate levels (AUC: 0.733 &#x000b1; 0.064; 95%CI: 0.607 -
0.858) in predicting which patients would respond to transfusion with an increase in
ScvO<sub>2</sub> greater than 5% (<xref ref-type="fig" rid="f02">Figure
2</xref>).</p><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Pre- and post-transfusion comparison of lactate, central venous oxygen saturation
and hemoglobin levels</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1"><bold>Variables</bold></th><th align="center" rowspan="1" colspan="1"><bold>Liberal</bold></th><th align="center" rowspan="1" colspan="1"><bold>Restrictive</bold></th><th rowspan="2" align="center" colspan="1"><bold>p value<xref ref-type="table-fn" rid="TFN04">*</xref></bold></th></tr><tr><th align="center" rowspan="1" colspan="1"><bold>(N = 39)</bold></th><th align="center" rowspan="1" colspan="1"><bold>(N = 35)</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;PreT Hb</td><td align="center" rowspan="1" colspan="1">8.5 (8.2 - 8.7)</td><td align="center" rowspan="1" colspan="1">6.8 (6.6 - 6.9)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;PosT Hb</td><td align="center" rowspan="1" colspan="1">9.4 (9.1 - 9.5)</td><td align="center" rowspan="1" colspan="1">7.6 (7.4 - 7.8)</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.0001</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Difference</td><td align="center" rowspan="1" colspan="1">0.9 (0.8 - 1.1)</td><td align="center" rowspan="1" colspan="1">0.9 (0.8 - 1.1)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;p value<xref ref-type="table-fn" rid="TFN03">#</xref></td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.0001</td><td align="center" rowspan="1" colspan="1">&#x0003c; 0.0001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">ScvO<sub>2</sub> (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;PreT ScvO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">72.0 (69.0- 74.0)</td><td align="center" rowspan="1" colspan="1">68.0 (64.0 - 72.0)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;PosT ScvO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">72.0 (71.0 - 73.0)</td><td align="center" rowspan="1" colspan="1">72.0 (69.0 - 75.0)</td><td align="center" rowspan="1" colspan="1">0.45</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Difference</td><td align="center" rowspan="1" colspan="1">-1.0 (-3.0 - 3.0)</td><td align="center" rowspan="1" colspan="1">4.0 (2.0 - 6.0)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;p value<xref ref-type="table-fn" rid="TFN03">#</xref></td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.0001</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Lactate (mMol/L)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;PreT lactate</td><td align="center" rowspan="1" colspan="1">1.90 (1.80 - 2.65)</td><td align="center" rowspan="1" colspan="1">2.44 (2.00 - 3.22)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;PosT lactate</td><td align="center" rowspan="1" colspan="1">2.00 (1.70 -- 2.41)</td><td align="center" rowspan="1" colspan="1">2.21 (1.80 - 2.79)</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;Difference</td><td align="center" rowspan="1" colspan="1">- 0.09 (- 0.50 - 0.20)</td><td align="center" rowspan="1" colspan="1">- 0.19 (-0.40 - 0.10</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;p value<xref ref-type="table-fn" rid="TFN03">#</xref></td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn><p>Hb - hemoglobin; ScvO<sub>2</sub> - central venous oxygen saturation; PreT -
pre-transfusion; PosT - post-transfusion. The results are expressed as the
median values (25 - 75%).</p></fn><fn id="TFN03"><label>#</label><p>p value refers to comparison within the same group (Wilcoxon rank test).</p></fn><fn id="TFN04"><label>*</label><p>p value refers to differences between groups (Mann-Whitney test).</p></fn></table-wrap-foot></table-wrap><fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Receiver operating characteristic curves comparing the ability of pre-transfusion
hemoglobin levels and central venous oxygen saturation to discriminate responders
and non-responders to transfusion in septic shock patients with pre-transfusion
central venous oxygen saturation levels below 75%. Responders were defined as
patients with an increase &#x02265; 5%. The ROC curve areas were as follows:
ScvO<sub>2</sub>: 0.879 &#x000b1; 0.048; 95%CI: 0.785 - 0.973, p &#x0003c; 0.0001);
Hb levels: 0.680 &#x000b1; 0.067; 95%CI: 0.548 - 0.812, p = 0.014).</p><p>Hb - hemoglobin; PreT Hb - pre-transfusion hemoglobin levels; PreT
ScvO<sub>2</sub> - pre-transfusion central venous oxygen saturation.</p></caption><graphic xlink:href="rbti-27-01-0036-g02"/></fig><p>In 34 transfusions, high lactate levels were present at baseline in 14 cases (35.9%) in
Group Hb9 and 20 cases (57.1%) in Group Hb7 (p = 0.06 for difference between groups). In
both groups, transfusion was associated with a significant reduction in lactate levels
(p = 0.02 and p = 0.001 for Groups Hb9 and Hb7, respectively;
<inline-supplementary-material xlink:href="rbti-27-01-0036-s01.pdf" mimetype="application" mime-subtype="pdf" id="d35e1004" content-type="local-data">Table S1 in the electronic supplementary
materials</inline-supplementary-material>). We found an improvement of at least 10%
in 64.3% and 45.0% of the transfusions in Group Hb9 and Hb7, respectively (p = 0.516).
However, only patients in Group Hb7 had low ScvO<sub>2</sub> levels at baseline, which
increased after transfusion.</p><p>Baseline ScvO<sub>2</sub> levels were less than 70% for 10 (25.6%) cases in Group Hb9
and for 20 (57.1%) cases in Group Hb7 (p = 0.005 between groups). In both groups,
ScvO<sub>2</sub> increased significantly after transfusion (p = 0.007 and p &#x0003c;
0.0001 for Groups Hb9 and Hb7, respectively; <inline-supplementary-material xlink:href="rbti-27-01-0036-s01.pdf" mimetype="application" mime-subtype="pdf" id="d35e1018" content-type="local-data">Table
S2 and Figure S1 in the electronic supplementary
materials</inline-supplementary-material>). We found an increase of at least 5% or to
values above 70% in 66.7% and 90% of the transfusions in Group Hb9 and Group Hb7,
respectively (p = 0.095).</p><p>We also analyzed the data by exploring only the first transfusion episode for each
patient; these results were similar with only slight changes in the p levels
(<inline-supplementary-material xlink:href="rbti-27-01-0036-s01.pdf" mimetype="application" mime-subtype="pdf" id="d35e1023" content-type="local-data">Table S3 in the electronic supplementary
material</inline-supplementary-material>).</p><p>In the transfusions for which the pre-transfusion lactate levels were normal (n = 40), a
decrease was detected on only six occasions (4 in Group Hb9 and 2 in Group Hb7 (p =
0.81). In 33 transfusions, baseline ScvO<sub>2</sub> was between 70% and 75%. Although
all four cases in which ScvO<sub>2</sub> decreased after transfusion were from Group
Hb9, this difference in distribution was not significant (p = 0.17;
<inline-supplementary-material xlink:href="rbti-27-01-0036-s01.pdf" mimetype="application" mime-subtype="pdf" id="d35e1035" content-type="local-data">Table S4 in the electronic supplementary
material</inline-supplementary-material>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this physiological prospective randomized study of septic shock patients, we
demonstrate that RBC transfusion leads to an increase in lactate and ScvO<sub>2</sub>
levels in patients with altered baseline levels, even if their Hb levels were between
7.0 and 9.0g/dL. No signs of worsened perfusion, as assessed by these variables, could
be found, even in patients with normal and higher levels of Hb. Moreover, we found that
pre-transfusion ScvO<sub>2</sub> was a better predictor of an increase in
ScvO<sub>2</sub> with transfusion than pre-transfusional Hb or lactate levels.</p><p>Hemoglobin level is one of the determinants of oxygen delivery. As expected, patients
randomized to the Group Hb7, who consequently had lower levels of Hb, had a higher
frequency of lower levels of ScvO<sub>2</sub> and higher lactate levels. However, the
threshold at which oxygen supply is impaired due to Hb in critically ill patients is not
known. Maintaining Hb levels at 7.0g/dL has been considered safe, primarily as a result
of a previous randomized study conducted in a general population of critically ill but
stable patients.<sup>(<xref rid="r25" ref-type="bibr">25</xref>)</sup> However, there
has been no randomized study comparing transfusion triggers in cases of impaired oxygen
delivery/oxygen consumption ratio status, as found in septic patients. The recent
published study of Holst et al., in which septic shock patients were randomized to a
restrictive group (transfusion only if Hb &#x0003c; 7.0g/dl) or a liberal group (transfusion
if Hb &#x0003c; 9.0g/dL) did not show differences between the groups, favoring the
restrictive approach.<sup>(<xref rid="r21" ref-type="bibr">21</xref>)</sup> However, the
study design did not focus on the presence of hypoperfusion because patients were
transfused when Hb fell below each group trigger during their entire ICU stay regardless
the presence of shock or signs of hypoperfusion.</p><p>Although this study is small with only physiological endpoints, its results suggests
that the presence of hyperlactatemia or low ScvO<sub>2</sub> should be considered in
future clinical studies that address this problem. It might be possible that a liberal
approach is superior to a restrictive one when considering only patients who actually
need to improve their oxygen delivery. Thus, if only patients with Hb levels &#x02264;
9.0g/dL were included and the presence of signs of hypoperfusion were required to
indicate transfusion, we would be able to properly compare two strategies of
transfusion: an early transfusion strategy initiated when Hb levels drop below 9.0g/dL;
and a late transfusion strategy, when transfusions are indicated only when Hb drops
below 7.0g/dL.</p><p>A first step to such a randomized interventional study aimed at establishing the best Hb
levels in septic patients would be to determine if transfusion is able to lower lactate
and increase ScvO<sub>2</sub> levels, even in patients with intermediate Hb levels, as
shown in this study. The effect of Hb on hemodynamic variables has been previously
demonstrated by Adamczyk et al.<sup>(<xref rid="r18" ref-type="bibr">18</xref>)</sup> in
postoperative patients for whom an improvement in ScvO<sub>2</sub> could be found only
in patients with lower ScvO<sub>2</sub> levels when their Hb levels were between 7.0g/dL
and 9.0g/dL. However, these authors did not analyze patients with the lower Hb levels
currently used as an indication for transfusion (i.e., below 7.0g/dL), which precludes
any attempt to relate responses to Hb levels. This improvement in tissue oxygenation may
have been related to an improvement in oxygen content; however, a possible mechanism
would have been the improvement of cardiac output secondary to an increase in preload.
This cannot be ruled out because this variable was not assessed in these patients. The
absence of this measurement is one of this study&#x02019;s limitations because it might
compromise the quality of the hemodynamic assessments presented. Although all patients
were stabilized before inclusion, and CVP levels were above 12mmHg, we did not measure
fluid responsiveness; thus, we cannot be certain that transfusion would not have led to
an increase in cardiac output.</p><p>However, this study has numerous strengths. First, the studied population is
homogeneous, only including septic shock patients. The majority of previous studies
included a heterogeneous population of critically ill individuals, such as surgical
patients without hemodynamic instability,<sup>(<xref rid="r26" ref-type="bibr">26</xref>)</sup> shock patients with multiple etiologies<sup>(<xref rid="r16" ref-type="bibr">16</xref>)</sup> or septic patients without shock.<sup>(<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r27" ref-type="bibr">27</xref>-<xref rid="r29" ref-type="bibr">29</xref>)</sup> Studies evaluating only septic shock patients were not
randomized and included only a small number of transfusions (e.g., 15 to 35
transfusions); as a result, they lacked statistical power to demonstrate slight
differences in these variables.<sup>(<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r17" ref-type="bibr">17</xref>)</sup> Second, the number of transfusions in
this study allowed us to analyze subgroups of patients with and without tissue
oxygenation abnormalities. This type of analysis was not emphasized in many previous
studies.<sup>(<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r26" ref-type="bibr">26</xref>)</sup> Third, the patients used in this study were randomized
into two different transfusion threshold levels. This strategy allows a comparison
between groups without any difference in disease severity, and a clear separation
regarding pre-transfusion Hb levels could be established.</p><p>Some limitations are also noteworthy. First, the evaluation of a transfusion&#x02019;s
beneficial and deleterious effects based only on ScvO<sub>2</sub> and lactate is
limited. The use of these variables to assess perfusion is also a limitation. We did not
assess any clinical outcomes. Second, patients were selected on a non-consecutive basis,
and more than one episode of transfusion per patient was registered, which could have
resulted in a selection bias. However, the transfusions were not given at the same time
point, and only one red blood cell unit was given at each time. This resulted in
different hemodynamic conditions and baseline Hb levels for each transfusion. We
recalculated data using only the first transfusion for each patient, and the results
were similar. Third, we might interpret the unknown storage duration as a limitation
because it precludes an eventual association of this variable with the transfusion
outcome. However, there are contradictory data regarding the relevance of storage time
to clinical, microcirculatory and physiological variables after transfusion.<sup>(<xref rid="r30" ref-type="bibr">30</xref>-<xref rid="r32" ref-type="bibr">32</xref>)</sup> Although we did not measure the storage period of the RBCs
transfused in this study, a previous report demonstrated that the median storage time of
RBCs in blood banks was 14 (7-21) days, suggesting that at least half of this study&#x02019;s
patients received fresh blood.<sup>(<xref rid="r33" ref-type="bibr">33</xref>)</sup>
Fourth, as already mentioned, the absence of cardiac output measurements and hemodynamic
data after transfusion prevents analysis of the correlation between tissue oxygenation
improvement and a possible increase in cardiac output secondary to increased preload
after transfusion. Fifth, although we collected post-transfusion blood samples
immediately after transfusion and there was no change in ventilator parameters or
arterial oxygenation, we cannot eliminate the possibility that the observed changes in
ScvO<sub>2</sub> and lactate could be influenced by modifications in oxygen
saturation, changes in oxygen consumption ratio or as a consequence of aerobic
glycolysis. Finally, we did not directly measure tissue perfusion.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>In conclusion, red blood cell transfusion in septic shock patients with low central
venous oxygen saturation or high lactate levels can result in an increase in central
venous oxygen saturation and a decrease in lactate levels in patients with hemoglobin
levels below 7.0g/dL and in patients with hemoglobin levels between 7.0 and 9.0g/dL. In
patients with normal lactate and central venous oxygen saturation levels, transfusion
did not change these variables, even in individuals with higher hemoglobin levels.</p></sec></body><back><fn-group><fn fn-type="conflict"><p><bold>Conflicts of interest</bold> None.</p></fn><fn fn-type="con"><p><bold>Authors&#x02019; contributions</bold></p><p>B. F. Mazza and F. R. Machado designed and coordinated this study; B. F. Mazza, F. G.
R. Freitas, M. M. O. Barros, L. C. P. Azevedo and F. R. Machado contributed to data
collection; B. F. Mazza and F. R. Machado drafted the manuscript; and B. F. Mazza, L.
C. P. Azevedo, F. G. R. Freitas and F. R. Machado revised the article. All authors
have read and approved the final manuscript.</p></fn><fn fn-type="other"><p><bold>Responsible editor:</bold> Gilberto Friedman</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>We are grateful to the healthcare professionals from the participating intensive care
units in the following institutions: Anesthesiology, Pain and Critical Care Discipline -
<italic>Universidade Federal de S&#x000e3;o Paulo</italic>, S&#x000e3;o Paulo, Brazil;
<italic>Santa Casa de Misericordia</italic>, Cruzeiro (SP), Brazil and
<italic>Hospital Antoninho da Rocha Marmo, S&#x000e3;o Jos&#x000e9; dos Campos</italic>
- SP, Brazil.</p></ack><ref-list><title>REFERENCES</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Linde-Zwirble</surname><given-names>WT</given-names></name><name><surname>Lidicker</surname><given-names>J</given-names></name><name><surname>Clermont</surname><given-names>G</given-names></name><name><surname>Carcillo</surname><given-names>J</given-names></name><name><surname>Pinsky</surname><given-names>MR</given-names></name></person-group><article-title>Epidemiology of severe sepsis in the United States: analysis of
incidence, outcome, and associated costs of care</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><issue>7</issue><fpage>1303</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">11445675</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>GS</given-names></name><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Moss</surname><given-names>M</given-names></name></person-group><article-title>The epidemiology of sepsis in the United States from 1979 through
2000</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>16</issue><fpage>1546</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">12700374</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Lipman</surname><given-names>J</given-names></name><name><surname>French</surname><given-names>C</given-names></name><name><surname>Dobb</surname><given-names>G</given-names></name><name><surname>Myburgh</surname><given-names>J</given-names></name></person-group><article-title>Adult-population incidence of severe sepsis in Australian and New
Zealand intensive care units</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><issue>4</issue><fpage>589</fpage><lpage>596</lpage><comment>Erratum in Intensive Care Med. 2004;30(6):1252</comment><pub-id pub-id-type="pmid">14963646</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>GS</given-names></name></person-group><article-title>A global perspective on the epidemiology of sepsis</article-title><source>Intensive Care Med</source><year>2004</year><volume>30</volume><issue>4</issue><fpage>527</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">14985955</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padkin</surname><given-names>A</given-names></name><name><surname>Goldfrad</surname><given-names>C</given-names></name><name><surname>Brady</surname><given-names>AR</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>N</given-names></name><name><surname>Rowan</surname><given-names>K</given-names></name></person-group><article-title>Epidemiology of severe sepsis occurring in the first 24 hrs in
intensive care units in England, Wales, and Northern Ireland</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>9</issue><fpage>2332</fpage><lpage>2338</lpage><pub-id pub-id-type="pmid">14501964</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvo</surname><given-names>I</given-names></name><name><surname>de Cian</surname><given-names>W</given-names></name><name><surname>Musicco</surname><given-names>M</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><name><surname>Piadena</surname><given-names>R</given-names></name><name><surname>Wolfler</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Italian SEPSIS study: preliminary results on the incidence and
evolution of SIRS, sepsis, severe sepsis and septic shock</article-title><source>Intensive Care Med</source><year>1995</year><volume>21</volume><issue>Suppl 2</issue><fpage>S244</fpage><lpage>S249</lpage><pub-id pub-id-type="pmid">8636531</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>E</given-names></name><name><surname>Pedro Mde</surname><given-names>A</given-names></name><name><surname>Sogayar</surname><given-names>AC</given-names></name><name><surname>Mohovic</surname><given-names>T</given-names></name><name><surname>Silva</surname><given-names>CL</given-names></name><name><surname>Janiszewski</surname><given-names>M</given-names></name><name><surname>Cal</surname><given-names>RG</given-names></name><name><surname>de Sousa</surname><given-names>EF</given-names></name><name><surname>Abe</surname><given-names>TP</given-names></name><name><surname>de Andrade</surname><given-names>J</given-names></name><name><surname>de Matos</surname><given-names>JD</given-names></name><name><surname>Rezende</surname><given-names>E</given-names></name><name><surname>Assun&#x000e7;&#x000e3;o</surname><given-names>M</given-names></name><name><surname>Avezum</surname><given-names>A</given-names></name><name><surname>Rocha</surname><given-names>PC</given-names></name><name><surname>de Matos</surname><given-names>GF</given-names></name><name><surname>Bento</surname><given-names>AM</given-names></name><name><surname>Corr&#x000ea;a</surname><given-names>AD</given-names></name><name><surname>Vieira</surname><given-names>PC</given-names></name><name><surname>Knobel</surname><given-names>E</given-names></name><collab>Brazilian Sepsis Epidemiological Study</collab></person-group><article-title>Brazilian Sepsis Epidemiological Study (BASES study)</article-title><source>Crit Care</source><year>2004</year><volume>8</volume><issue>4</issue><fpage>R251</fpage><lpage>R260</lpage><pub-id pub-id-type="pmid">15312226</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sogayar</surname><given-names>AM</given-names></name><name><surname>Machado</surname><given-names>FR</given-names></name><name><surname>Rea-Neto</surname><given-names>A</given-names></name><name><surname>Dornas</surname><given-names>A</given-names></name><name><surname>Grion</surname><given-names>CM</given-names></name><name><surname>Lobo</surname><given-names>SM</given-names></name><name><surname>Tura</surname><given-names>BR</given-names></name><name><surname>Silva</surname><given-names>CL</given-names></name><name><surname>Cal</surname><given-names>RG</given-names></name><name><surname>Beer</surname><given-names>I</given-names></name><name><surname>Michels</surname><given-names>V</given-names></name><name><surname>Safi</surname><given-names>J</given-names></name><name><surname>Kayath</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>E</given-names></name><collab>Costs Study Group - Latin American Sepsis Institute</collab></person-group><article-title>A multicentre, prospective study to evaluate costs of septic patients
in Brazilian intensive care units</article-title><source>Pharmacoeconomics</source><year>2008</year><volume>26</volume><issue>5</issue><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">18429658</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>RS</given-names></name><name><surname>Karl</surname><given-names>IE</given-names></name></person-group><article-title>Reevaluation of the role of cellular hypoxia and bioenergetic failure
in sepsis</article-title><source>JAMA</source><year>1992</year><volume>267</volume><issue>11</issue><fpage>1503</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">1538541</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weg</surname><given-names>JG</given-names></name></person-group><article-title>Oxygen transport in adult respiratory distress syndrome and other
acute circulatory problems: relationship of oxygen delivery and oxygen
consumption</article-title><source>Crit Care Med</source><year>1991</year><volume>19</volume><issue>5</issue><fpage>650</fpage><lpage>657</lpage><comment>Review</comment><pub-id pub-id-type="pmid">2026027</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e9;bert</surname><given-names>PC</given-names></name><name><surname>Tinmouth</surname><given-names>A</given-names></name><name><surname>Corwin</surname><given-names>H</given-names></name></person-group><article-title>Anemia and red cell transfusion in critically ill
patients</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>12</issue><supplement>Suppl</supplement><fpage>S672</fpage><lpage>S677</lpage><pub-id pub-id-type="pmid">14724465</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorente</surname><given-names>JA</given-names></name><name><surname>Land&#x000ed;n</surname><given-names>L</given-names></name><name><surname>De Pablo</surname><given-names>R</given-names></name><name><surname>Renes</surname><given-names>E</given-names></name><name><surname>Rodr&#x000ed;guez-D&#x000ed;az</surname><given-names>R</given-names></name><name><surname>Liste</surname><given-names>D</given-names></name></person-group><article-title>Effects of blood transfusion on oxygen transport variables in severe
sepsis</article-title><source>Crit Care Med</source><year>1993</year><volume>21</volume><issue>9</issue><fpage>1312</fpage><lpage>1318</lpage><pub-id pub-id-type="pmid">8370294</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>HJ</given-names></name><name><surname>Tuma</surname><given-names>P</given-names></name></person-group><article-title>Gastric tonometry in patients with sepsis. Effects of dobutamine
infusions and packed red blood cell transfusions</article-title><source>Chest</source><year>1992</year><volume>102</volume><issue>1</issue><fpage>184</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">1623750</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marik</surname><given-names>PE</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name></person-group><article-title>Effect of stored-blood transfusion on oxygen delivery in patients with
sepsis</article-title><source>JAMA</source><year>1993</year><volume>269</volume><issue>23</issue><fpage>3024</fpage><lpage>3029</lpage><pub-id pub-id-type="pmid">8501845</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>SA</given-names></name><name><surname>Dietrich</surname><given-names>KA</given-names></name><name><surname>Hebert</surname><given-names>CA</given-names></name><name><surname>Romero</surname><given-names>MD</given-names></name></person-group><article-title>Effect of red cell transfusion on oxygen consumption following fluid
resuscitation in septic shock</article-title><source>Circ Shock</source><year>1990</year><volume>31</volume><issue>4</issue><fpage>419</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">2397567</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>KA</given-names></name><name><surname>Conrad</surname><given-names>SA</given-names></name><name><surname>Hebert</surname><given-names>CA</given-names></name><name><surname>Levy</surname><given-names>GL</given-names></name><name><surname>Romero</surname><given-names>MD</given-names></name></person-group><article-title>Cardiovascular and metabolic response to red blood cell transfusion in
critically ill volume-resuscitated nonsurgical patients</article-title><source>Crit Care Med</source><year>1990</year><volume>18</volume><issue>9</issue><fpage>940</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">2394117</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazza</surname><given-names>BF</given-names></name><name><surname>Machado</surname><given-names>FR</given-names></name><name><surname>Mazza</surname><given-names>DD</given-names></name><name><surname>Hassmann</surname><given-names>V</given-names></name></person-group><article-title>Evaluation of blood transfusion effects on mixed venous oxygen
saturation and lactate levels in patients with SIRS/sepsis</article-title><source>Clinics (Sao Paulo)</source><year>2005</year><volume>60</volume><issue>4</issue><fpage>311</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">16138238</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamczyk</surname><given-names>S</given-names></name><name><surname>Robin</surname><given-names>E</given-names></name><name><surname>Barreau</surname><given-names>O</given-names></name><name><surname>Fleyfel</surname><given-names>M</given-names></name><name><surname>Tavernier</surname><given-names>B</given-names></name><name><surname>Lebuffe</surname><given-names>G</given-names></name><etal/></person-group><article-title>Contribution of central venous oxygen saturation in postoperative
blood transfusion decision</article-title><source>Ann Fr Anesth Reanim</source><year>2009</year><volume>28</volume><issue>6</issue><fpage>522</fpage><lpage>530</lpage><comment>French</comment><pub-id pub-id-type="pmid">19467825</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creteur</surname><given-names>J</given-names></name><name><surname>Neves</surname><given-names>AP</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Near-infrared spectroscopy technique to evaluate the effects of red
blood cell transfusion on tissue oxygenation</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><issue>Suppl 5</issue><fpage>S11</fpage><pub-id pub-id-type="pmid">19951383</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivers</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>B</given-names></name><name><surname>Havstad</surname><given-names>S</given-names></name><name><surname>Ressler</surname><given-names>J</given-names></name><name><surname>Muzzin</surname><given-names>A</given-names></name><name><surname>Knoblich</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>E</given-names></name><name><surname>Tomlanovich</surname><given-names>M</given-names></name><collab>Early Goal-Directed Therapy Collaborative Group</collab></person-group><article-title>Early goal-directed therapy in the treatment of severe sepsis and
septic shock</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>19</issue><fpage>1368</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">11794169</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname><given-names>LB</given-names></name><name><surname>Haase</surname><given-names>N</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><name><surname>Wernerman</surname><given-names>J</given-names></name><name><surname>Guttormsen</surname><given-names>AB</given-names></name><name><surname>Karlsson</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>PI</given-names></name><name><surname>Aneman</surname><given-names>A</given-names></name><name><surname>Vang</surname><given-names>ML</given-names></name><name><surname>Winding</surname><given-names>R</given-names></name><name><surname>Nebrich</surname><given-names>L</given-names></name><name><surname>Nibro</surname><given-names>HL</given-names></name><name><surname>Rasmussen</surname><given-names>BS</given-names></name><name><surname>Lauridsen</surname><given-names>JR</given-names></name><name><surname>Nielsen</surname><given-names>JS</given-names></name><name><surname>Oldner</surname><given-names>A</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V</given-names></name><name><surname>Cronhjort</surname><given-names>MB</given-names></name><name><surname>Andersen</surname><given-names>LH</given-names></name><name><surname>Pedersen</surname><given-names>UG</given-names></name><name><surname>Reiter</surname><given-names>N</given-names></name><name><surname>Wiis</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>JO</given-names></name><name><surname>Russell</surname><given-names>L</given-names></name><name><surname>Thornberg</surname><given-names>KJ</given-names></name><name><surname>Hjortrup</surname><given-names>PB</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>RG</given-names></name><name><surname>M&#x000f8;ller</surname><given-names>MH</given-names></name><name><surname>Steensen</surname><given-names>M</given-names></name><name><surname>Tj&#x000e4;der</surname><given-names>I</given-names></name><name><surname>Kilsand</surname><given-names>K</given-names></name><name><surname>Odeberg-Wernerman</surname><given-names>S</given-names></name><name><surname>Sj&#x000f8;b&#x000f8;</surname><given-names>B</given-names></name><name><surname>Bundgaard</surname><given-names>H</given-names></name><name><surname>Thy&#x000f8;</surname><given-names>MA</given-names></name><name><surname>Lodahl</surname><given-names>D</given-names></name><name><surname>Maerkedahl</surname><given-names>R</given-names></name><name><surname>Albeck</surname><given-names>C</given-names></name><name><surname>Illum</surname><given-names>D</given-names></name><name><surname>Kruse</surname><given-names>M</given-names></name><name><surname>Winkel</surname><given-names>P</given-names></name><name><surname>Perner</surname><given-names>A</given-names></name><collab>TRISS Trial Group</collab><collab>Scandinavian Critical Care Trials Group</collab></person-group><article-title>Lower versus higher hemoglobin threshold for transfusion in septic
shock</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>15</issue><fpage>1381</fpage><lpage>1391</lpage><pub-id pub-id-type="pmid">25270275</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Cerra</surname><given-names>FB</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Fein</surname><given-names>AM</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Definitions for sepsis and organ failure and guidelines for the use of
innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee.
American College of Chest Physicians/Society of Critical Care
Medicine</article-title><source>Chest</source><year>1992</year><volume>101</volume><issue>6</issue><fpage>1644</fpage><lpage>1655</lpage><pub-id pub-id-type="pmid">1303622</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Draper</surname><given-names>EA</given-names></name><name><surname>Wagner</surname><given-names>DP</given-names></name><name><surname>Zimmerman</surname><given-names>JE</given-names></name></person-group><article-title>APACHE II: a severity of disease classification system</article-title><source>Crit Care Med</source><year>1985</year><volume>13</volume><issue>10</issue><fpage>818</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">3928249</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name><name><surname>Willatts</surname><given-names>S</given-names></name><name><surname>De Mendonca</surname><given-names>A</given-names></name><name><surname>Bruining</surname><given-names>H</given-names></name><etal/></person-group><article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe
organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related
Problems of the European Society of Intensive Care Medicine</article-title><source>Intensive Care Med</source><year>1996</year><volume>22</volume><issue>7</issue><fpage>707</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">8844239</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e9;bert</surname><given-names>PC</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Blajchman</surname><given-names>MA</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Pagliarello</surname><given-names>G</given-names></name><etal/></person-group><article-title>A multicenter, randomized, controlled clinical trial of transfusion
requirements in critical care. Transfusion Requirements in Critical Care
Investigators, Canadian Critical Care Trials Group</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><issue>6</issue><fpage>409</fpage><lpage>417</lpage><comment>Erratum in N Engl J Med 1999;340(13):1056</comment><pub-id pub-id-type="pmid">9971864</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babineau</surname><given-names>TJ</given-names></name><name><surname>Dzik</surname><given-names>WH</given-names></name><name><surname>Borlase</surname><given-names>BC</given-names></name><name><surname>Baxter</surname><given-names>JK</given-names></name><name><surname>Bistrian</surname><given-names>BR</given-names></name><name><surname>Benotti</surname><given-names>PN</given-names></name></person-group><article-title>Reevaluation of current transfusion practices in patients in surgical
intensive care units</article-title><source>Am J Surg</source><year>1992</year><volume>164</volume><issue>1</issue><fpage>22</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">1626602</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steffes</surname><given-names>CP</given-names></name><name><surname>Bender</surname><given-names>JS</given-names></name><name><surname>Levison</surname><given-names>MA</given-names></name></person-group><article-title>Blood transfusion and oxygen consumption in surgical
sepsis</article-title><source>Crit Care Med</source><year>1991</year><volume>19</volume><issue>4</issue><fpage>512</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">2019137</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakr</surname><given-names>Y</given-names></name><name><surname>Chierego</surname><given-names>M</given-names></name><name><surname>Piagnerelli</surname><given-names>M</given-names></name><name><surname>Verdant</surname><given-names>C</given-names></name><name><surname>Dubois</surname><given-names>MJ</given-names></name><name><surname>Koch</surname><given-names>M</given-names></name><etal/></person-group><article-title>Microvascular response to red blood cell transfusion in patients with
severe sepsis</article-title><source>Crit Care Med</source><year>2007</year><volume>35</volume><issue>7</issue><fpage>1639</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">17522571</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>CJ</given-names><suffix>Jr</suffix></name><name><surname>Akamine</surname><given-names>N</given-names></name><name><surname>De Marco</surname><given-names>FV</given-names></name><name><surname>De Souza</surname><given-names>JA</given-names></name><name><surname>Lagudis</surname><given-names>S</given-names></name><name><surname>Knobel</surname><given-names>E</given-names></name></person-group><article-title>Red blood cell transfusion does not increase oxygen consumption in
critically ill septic patients</article-title><source>Crit Care</source><year>2001</year><volume>5</volume><issue>6</issue><fpage>362</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">11737926</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frenzel</surname><given-names>T</given-names></name><name><surname>Westphal-Varghese</surname><given-names>B</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name></person-group><article-title>Role of storage time of red blood cells on microcirculation and tissue
oxygenation in critically ill patients</article-title><source>Curr Opin Anaesthesiol</source><year>2009</year><volume>22</volume><issue>2</issue><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">19390254</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelubre</surname><given-names>C</given-names></name><name><surname>Piagnerelli</surname><given-names>M</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Association between duration of storage of transfused red blood cells
and morbidity and mortality in adult patients: myth or reality?</article-title><source>Transfusion</source><year>2009</year><volume>49</volume><issue>7</issue><fpage>1384</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">19453985</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vamvakas</surname><given-names>EC</given-names></name></person-group><article-title>Meta-analysis of clinical studies of the purported deleterious effects
of "old" (versus "fresh") red blood cells: are we at equipoise?</article-title><source>Transfusion</source><year>2010</year><volume>50</volume><issue>3</issue><fpage>600</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">20042031</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assuncao</surname><given-names>M</given-names></name><name><surname>Paula</surname><given-names>I</given-names></name><name><surname>Falcao</surname><given-names>L</given-names></name><name><surname>Mazza</surname><given-names>B</given-names></name><name><surname>Barros</surname><given-names>M</given-names></name><name><surname>Jackiu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transfusion profile in intensive care units from a university
hospital</article-title><source>Critical Care</source><year>2007</year><volume>11</volume><issue>Suppl 2</issue><fpage>P412</fpage></element-citation></ref></ref-list></back></article>